Business
Interim Results
Interim Results.
About this update from Amirose London Holdings Plc
[{"type":"text","content":"\n\nThe information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n \nPress Release \n31 August 2023\nClarify Pharma PLC\n \n(\"Clarify Pharma\" or \"The Company\")\n \nInterim results\n \nClarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, announces its unaudited financial results for the six months ended 31 May 2023.\n \nExecutive Director's Statement Introduction\nI am pleased to report the Company's interim set of results for the six months ended 31 May 2023.\n \nThe Company held cash and cash equivalents of £212,000 as at 31 May 2023. Cash and cash equivalents amounted to £183,000as at 31 August 2023.\n \nThe potential benefits of psychedelic drugs have been recognised in both the UK and the US and the medical use of psychedelics is progressively emerging as an alternative candidate to conventional therapies for individuals suffering from elusive maladies like PTSD, addiction, Alzheimer's and depression.\n \nWe see opportunities for investing in companies with the required expertise and potential to become pioneers in the market. Psychedelic assisted therapy is in its earliest days of development, particularly in the UK. There is a new window of opportunity as the industry continues to gain more traction and credibility as a result of new scientific research and evidence. We look forward to capitalising on these promising long-term trends in this cutting-edge medical frontier.\n \nSo as to maximise the Company's runway the Directors have, since the end of March 2023, deferred being paid any Director fees.\n \nI would also like to take this opportunity to thank all our shareholders for their support.\n \nJonathan Bixby, Executive Director\n \nPrincipal risks and uncertainties\n \nThe directors have assessed the operational environment of the Company and concluded that the principal risks and uncertainties have not ...